Objective
to investigate whether DAPT (aspirin + ticagrelor) for 1 month followed by monotherapy ticagrelor 1 year is non-inferior to 12 months ticagrelor +aspirin therapy
Study
investigator-initiated, open-label multicentre randomised non-inferiority study (margin 30% HR scale)
Population
patients with ACS and DES implantation (ORSIRO)
Endpoints
1 year net clinical benefit as composite of all-cause death, MI, stent thrombosis, stroke and major bleeding (BARC 3 to 5)
Conclusion
stopping aspirin within 1 month for ticagrelor monotherapy is both non-inferior and superior to 12-month DAPT in terms of net clinical benefit in patients with ACS.
Hong et al. Circulation 2024;149:562-573
